-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Sponsor: Sanofi and Takeda Pharmaceuticals USA, Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Drug development, Education, Treatment Considerations
Friday, December 6, 2024: 11:00 AM-2:00 PM
Room 6A (San Diego Convention Center)
Chair:
Krina K. Patel, MD, MSc, The University of Texas MD Anderson Cancer Center
Disclosures:
Patel: BMS: Consultancy, Other: chair of scientific advisory board ; Poseida: Consultancy; Merck: Consultancy; Sanofi: Consultancy; AstraZeneca: Consultancy; Johnson & Johnson (Janssen): Consultancy; Abbvie: Consultancy; Caribou Sciences: Consultancy; Kite, A Gilead company: Consultancy, Other: scientific advisory board; Genentech: Consultancy; Takeda: Consultancy; Pfizer: Consultancy; Oricel: Consultancy, Other: Chair of scientific board.
Speakers:
Ajay K. Nooka, MD, MPH, Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University and Alfred L. Garfall, MD, University of Pennsylvania Abramson Cancer Center
Disclosures:
Nooka: Aduro Biotech: Research Funding; Arch Oncology: Research Funding; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Cellectar Biosciences: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Research Funding; Sebia: Honoraria, Membership on an entity's Board of Directors or advisory committees; Cellectis: Research Funding; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; K36 Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; ONK Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm: Research Funding; Kite Pharma: Research Funding; Merck: Research Funding. Garfall: GSK: Consultancy; Amgen: Consultancy; Novartis: Research Funding; Tmunity Therapeutics: Research Funding; Crispr: Research Funding; Janssen: Consultancy, Research Funding.

On Demand program will be available here December 7, 2024.

Access Program Here

  • The live portion will be presented as a 3.0-hour Satellite Symposium held prior to the 2024 ASH Annual Meeting.
    • This satellite program will bring together four experts to highlight novel agents in the management of MM, including the latest clinical trial data and strategies to manage ND, and R/R MM including a discussion of the latest data
    • The program will also integrate a real-world component to highlight how these case scenarios are handled in the community, to shed light on the potential gaps between clinical trial experience and real world application. PER will identify community oncologists who will submit pre-recorded videos explaining their challenges and barriers to care. Following these real-world videos, experts will propose solutions to be applied to bridge the gaps. Learners will also be given the chance to bring forward their own challenges.
  • To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.
  • The program will also be live-streamed on our website for the benefit of those unable to attend in person.
See more of: Friday Satellite Symposia
<< Previous Application | Next Application >>